China's drug regulator granted Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) a supplemental drug approval for its cefuroxime sodium injection and candesartan cilexetil tablets, according to a Tuesday filing with the Shanghai bourse.
The approvals cover supplementary research.
Cefuroxime sodium is indicated for acute respiratory, urinary tract, and other bacterial infections, while
Candesartan cilexetil is indicated for hypertension.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.